. 2015 Jul 17;2(11):1500053. doi: 10.1002/advs.201500053

Table 1.

Authorized medicines for breast cancer in the European Union (EU) by the European Medicines Agency (EMA), and in the USA by the Food and Drug Administration (FDA)

Class	Common name	Trade name	Condition	Approval date	Regulator
Mitotic inhibitors (non‐taxanes)	Eribulin mesylate	Halaven	Metastatic BC^a)Locally advanced or metastatic BC^a)	11/201003/2011	FDAEMA
Mitotic inhibitors (epothilones)	Ixabepilone	Ixempra	Locally advanced or metastatic BC^a)	10/2007	FDA
Mitotic inhibitors (taxanes)	Albumin‐bound paclitaxel	Abraxane	Locally advanced or metastatic BC^a)	01/2008	EMA
	Docetaxel	Docetaxel AccordDocetaxel KabiDocetaxel MylanDocetaxel TevaDocetaxel Winthrop	BC^a)BC^a)BC^a)BC^a)BC^a)	05/201205/201201/201201/201004/2007	EMAEMAEMAEMAEMA
		Taxotere	BC^a)Locally advanced or metastatic BC^a)	11/199505/1996	EMAFDA
Anthracyclines	Liposomal doxorubicin hydrochloride	CaelyxMyocet	Metastatic BC^a)	06/199607/2000	EMAEMA
Anti‐metabolites	Capecitabine	EcansyaCapecitabine AccordCapecitabine SUNCapecitabine Teva	Locally advanced or metastatic BC^a)Locally advanced or metastatic BC^a)Locally advanced or metastatic BC^a)Locally advanced or metastatic BC^a)	04/201204/201206/201304/2012	EMAEMAEMAEMA
		Xeloda	Locally advanced or metastatic BC^a)Advanced BC^a)	02/200104/1998	EMAFDA
Bisphosphonates	Pamidronate disodium	Aredia	Bone metastases	08/1996	FDA
Tyrosine kinase inhibitors	Lapatinib	Tykerb	HER2+^b) advanced or metastatic BC^a)	03/200706/2008	FDAEMA
Serine/threonine kinase inhibitors	Everolimus	Afinitor	ER+^c)/PR+^d)/HER2‐^b) advanced BC^a)	08/200907/2012	EMAFDA
Aromatase inhibitors	Anastrozole	Arimidex	Advanced BC^a)	01/1996	FDA
	Letrozole	Femara	BC^a)Advanced or metastatic BC^a)	07/199701/2001	FDAFDA
SERMs^e)	Fulvestrant	Faslodex	ER+^c) metastatic BC^a)ER+^c)/PR+^d) metastatic BC^a)	10/199802/1996	FDAEMA
	Tamoxifen	Nolvadex	ER+^c) metastatic BC^a)	10/1996	FDA
	Toremifene	Fareston	ER+^c)/PR+^d) metastatic BC^a)	02/1996	EMA
Monoclonal antibodies	Bevacizumab	Avastin	Metastatic BC^a)	01/2005	EMA
	Pertuzumab	Perjeta	HER2+^b) locally recurrent or metastatic BC^a)HER2+^b) metastatic BC^a)	03/201306/2012	EMAFDA
	Trastuzumab	Herceptin	Early BC^a)Metastatic BC^a)	08/200010/1998	EMAFDA
	(Ado)‐trastuzumab emtansine (trastuzumab linked to DM1 drug)	Kadcyla	HER2+^b) locally advanced or metastatic BC^a)	11/201302/2013	EMAFDA

^a)BC: breast cancer;

^b)HER2+/HER2‐: human epidermal growth factor receptor 2 positive/negative;

^c)ER+/–: estrogen receptor positive/negative;

^d)PR+/–: progesterone receptor positive/negative;

^e)SERMs: selective estrogen‐receptor response modulators.134, 135